Press release - 25/01/2021 Protein anchors as a newly discovered key molecule in cancer spread and epilepsy Certain anchor proteins inhibit a key metabolic driver that plays an important role in cancer and developmental brain disorders. Scientists from the German Cancer Research Center (DKFZ) and the University of Innsbruck, together with a Europe-wide research network, discovered this molecular mechanism, which could open up new opportunities for personalized therapies for cancer and neuronal diseases. They published their results in the journal Cell.https:////www.gesundheitsindustrie-bw.de:443/en/article/press-release/protein-anchors-newly-discovered-key-molecule-cancer-spread-and-epilepsy
Article - 14/01/2021 Newly discovered RNA as growth driver in liver cancer Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.https:////www.gesundheitsindustrie-bw.de:443/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
Press release - 09/12/2020 Combatting cancer with biological circuits The Freiburg engineer and biologist Prof. Dr. Barbara Di Ventura receives a Consolidator Grant from the European Research Council (ERC), one of the most prestigious prizes for European researchers, for her project "InCanTeSiMo - Intelligent cancer therapy with synthetic biology methods". Di Ventura will use the 2 Million Euros to develop a novel cancer treatment based on molecular methods from synthetic biology.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/combatting-cancer-biological-circuits
Press release - 03/12/2020 HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-erreicht-meilenstein-mit-dem-nachweis-von-sicherheit-und-wirksamkeit-der-mkk4-inhibition-im-model-fuer-fortgeschritt
New method for analysing blood samples - 26/11/2020 Personalised therapy monitoring for malignant melanomas Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…https:////www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
Press release - 17/11/2020 The Long Road to Dementia The chain reaction which leads to toxic protein deposits in Alzheimer’s disease starts even earlier than assumed. Researchers from Tübingen show how this process could be stopped early on.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/long-road-dementia
Lab-on-a-chip - 11/11/2020 Microfluidic platform for the best possible cancer therapy Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.https:////www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
Press release - 09/11/2020 Infection diagnostics 3.0: Faster thanks to nanopore sequencing To ensure that sepsis patients receive appropriate antibiotics as quickly as possible, Fraunhofer IGB researchers have developed a diagnostic procedure that uses high-throughput sequencing of blood samples and delivers results much faster than conventional culture-based techniques. Thanks to the latest single-molecule sequencing techniques, this process has now been further improved so that pathogens can be identified after just a few hours.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/infection-diagnostics-30-faster-thanks-nanopore-sequencing
Press release - 04/11/2020 Which treatment is best for childhood brain tumors? Global trial receives funding of EUR 2.2m The German Childhood Cancer Foundation is providing EUR 2.2m to fund the phase III clinical trial to investigate the treatment options for certain types of childhood brain cancer with a chronic course. Initiated by the Hopp Children’s Cancer Center Heidelberg, the trial will compare two standard chemotherapy treatments and a targeted therapy to establish which is the most effective and well tolerated as a standard therapy for young patients.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/welche-behandlung-ist-die-beste-bei-hirntumoren-im-kindesalter-weltweite-studie-wird-mit-22-mio-euro-gefoerdert
Press release - 02/11/2020 Juvenile myelomonocytic leukemia: International classification model allows for customized treatment Juvenile myelomonocytic leukemia (JMML) is a rare blood cancer of early childhood. Previous research activities have shown that JMML patients can be divided into three groups based on certain genetic markers, DNA methylation. Depending on the subgroup, statements can be made about the course of the disease. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/juvenile-myelomonocytic-leukemia-international-classification-model-allows-customized-treatment
Press release - 26/10/2020 How to prevent the spread of tumor cells via the lymph vessels What role do the lymphatic vessels play in the metastasis of cancer cells? Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg developed a method to investigate this question in mice. The aim of the work was to identify new ways to block the dangerous colonization and spread of tumor cells. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/how-prevent-spread-tumor-cells-lymph-vessels
Press release - 20/10/2020 EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
Press release - 15/10/2020 Pancreatic cancer: Subtypes with different aggressiveness discovered Tumors of the pancreas are particularly feared. They are usually discovered late and mortality is high. Until now, no targeted and personalized therapies exist. Scientists at the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine* (HI-STEM) have now succeeded for the first time in defining two differently aggressive molecular subtypes of pancreatic carcinoma.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/pancreatic-cancer-subtypes-different-aggressiveness-discovered
Press release - 15/10/2020 Common Vulnerabilities of Coronaviruses International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/common-vulnerabilities-coronaviruses
Intestinal peptide heals lung - 14/10/2020 Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.https:////www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
Press release - 08/10/2020 New class of highly effective inhibitors protects against neurodegeneration Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-class-highly-effective-inhibitors-protects-against-neurodegeneration
Organ failure due to fatty liver - 24/09/2020 HepaRegeniX develops an active substance for liver regeneration When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure. https:////www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
Phytopharmaceuticals - 14/09/2020 Medicinal cannabis to be grown in Germany Anyone who thinks hemp is just an inconspicuous plant, whose ingredients can be used, at best, as an intoxicant, can quickly be proven wrong. Besides being used as a valuable raw material for textiles and building materials, the plant has great potential as a medicinal drug. The CANNABIS-NET network, coordinated by the University of Hohenheim, has been set up to establish the basis for producing medicinal hemp in Germany.https:////www.gesundheitsindustrie-bw.de/en/article/news/medicinal-cannabis-be-grown-germany
Innovative Therapies - 20/08/2020 Labor Dr. Merk is fully committed to viral therapies Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…https:////www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-fully-committed-viral-therapies
Press release - 11/08/2020 Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-announces-closing-eur-86-million-102-million-oversubscribed-convertible-loan
TGU Varimol - 24/07/2020 Click chemistry for new medical procedures Using a simple molecular click process, biochemists have been able to connect ring-shaped molecules with each other and couple therapeutically active substances to these molecules. Drugs can thus be specifically delivered to diseased cells and used for imaging processes or biosensors. The Stuttgart-based start-up Varimol is using this new technology to provide its customers with tailored applications that are as simple to use as a kit.https:////www.gesundheitsindustrie-bw.de/en/article/news/click-chemistry-new-medical-procedures
Stem cell therapy for regenerating intervertebral discs - 16/07/2020 Ulm’s simulator has Europe’s back Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.https:////www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
Review article (new edition) - 08/07/2020 Immunology – at the forefront of medical progress Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.https:////www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress
Press release - 15/06/2020 German Federal Government invests 300 Million Euros in CureVac The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/german-federal-government-invests-300-million-euros-curevac
Innovations in the field of endoscopy - 08/06/2020 Gastroscopies with pill cameras A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.https:////www.gesundheitsindustrie-bw.de/en/article/news/magenspiegelung-kamerapille